Iodine 131

NSF Award Accelerates SHINE Efforts to Become a Major Iodine-131 Producer

Press Releases
NSF Award Accelerates SHINE Efforts to Become a Major Iodine-131 Producer
No items found.

June 30, 2015 – Monona, WI SHINE Medical Technologies, a Wisconsin-based medical isotope company, announced today that it has been awarded $150,000 from the National Science Foundation for Phase I of an SBIR (Small Business Innovation Research) Grant. This grant will fast-track SHINE’s ongoing development of iodine-131 extraction and purification processes, which SHINE may decide to pursue at its medical isotope production facility.Iodine-131 is a medical isotope used widely for the treatment of Graves’ disease and cancer.

The U.S. currently has no domestic iodine-131 production capability and imports all of its supply from foreign producers. Most of these producers use weapons-grade uranium and rely on aging facilities that are increasingly prone to unexpected shutdowns. Further, the iodine- 131 supply chain is expected to become significantly more fragile when Canadian medical isotope production ceases in 2018.

“This award is another validation of SHINE’s process for making medical isotopes. NSF grants are very competitive and highly scrutinized for technical and scientific merit,” said Jeff Driscoll, Principal Scientist at SHINE. “Our work is a collaboration with the Department of Medical Physics at the University of Wisconsin—Madison School of Medicine and Public Health. We’re happy to be able to do what we can to preserve access to a reliable supply of an established medical therapy that benefits thousands of newly-diagnosed cancer patients each year.”

About SHINE Technologies

Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE’s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy’s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth. Want to learn more about SHINE? Follow us on social media @shinefusion and sign up for our email newsletter to follow us on our journey!

Media Contact: info@shinefusion.com

Lutetium-177 Information Sheet (EU Distribution)Ilumira Information Sheetdownload PDF RESOURCE HERE